Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (161-170 of 791) with videos related to

Pageof 80
Sort By:
Annals of Internal Medicine|December 21, 2006
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceHagop M Kantarjian, Moshe Talpaz, Francis Giles, et al.
Blood Reviews|July 3, 2014
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemiaMichael S Mathisen, Hagop M Kantarjian, Jorge Cortes, et al.
JAMA Network Open|August 28, 2024
Intersection of Poverty and Rurality for Early-Onset Colorectal Cancer SurvivalMeng-Han Tsai, Steven S Coughlin, Jorge Cortes, et al.
Blood|July 1, 2006
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemiaCraig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Leukemia Research|February 9, 2013
Chromosome 5q deletion is extremely rare in patients with myelofibrosisKoichi Takahashi, Jorge Cortes, Sherry Pierce, et al.
Leukemia & Lymphoma|December 5, 2008
Potential role of sorafenib in the treatment of acute myeloid leukemiaShahram Mori, Jorge Cortes, Hagop Kantarjian, et al.
Haematologica|November 5, 2013
Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcriptsPreetesh Jain, Carlos Guillermo Romo, Hanna J Khoury, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studiesHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Statistics in Medicine|January 11, 2016
A two-stage approach for dynamic prediction of time-to-event distributionsXuelin Huang, Fangrong Yan, Jing Ning, et al.
Future Oncology (London, England)|September 13, 2019
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III studyTimothy S Pardee, Sanjeev Luther, Marc Buyse, et al.
Pageof 80

Showing results (161-170 of 791) with videos related to

Sort By:
Pageof 80
Annals of Internal Medicine|December 21, 2006
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceHagop M Kantarjian, Moshe Talpaz, Francis Giles, et al.
Blood Reviews|July 3, 2014
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemiaMichael S Mathisen, Hagop M Kantarjian, Jorge Cortes, et al.
JAMA Network Open|August 28, 2024
Intersection of Poverty and Rurality for Early-Onset Colorectal Cancer SurvivalMeng-Han Tsai, Steven S Coughlin, Jorge Cortes, et al.
Blood|July 1, 2006
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemiaCraig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Leukemia Research|February 9, 2013
Chromosome 5q deletion is extremely rare in patients with myelofibrosisKoichi Takahashi, Jorge Cortes, Sherry Pierce, et al.
Leukemia & Lymphoma|December 5, 2008
Potential role of sorafenib in the treatment of acute myeloid leukemiaShahram Mori, Jorge Cortes, Hagop Kantarjian, et al.
Haematologica|November 5, 2013
Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcriptsPreetesh Jain, Carlos Guillermo Romo, Hanna J Khoury, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studiesHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Statistics in Medicine|January 11, 2016
A two-stage approach for dynamic prediction of time-to-event distributionsXuelin Huang, Fangrong Yan, Jing Ning, et al.
Future Oncology (London, England)|September 13, 2019
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III studyTimothy S Pardee, Sanjeev Luther, Marc Buyse, et al.
Pageof 80